Ilyda Quote - 0P0V | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Home
Investing
Stocks
UK
LSE
Ilyda Sa (0P0V) Share Price

Ilyda Sa (0P0V)

0.222

0.00

(0.00%)

Closed 05 January 3:30AM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Current Price

0.222

Bid

0.00

Offer

0.00

Volume

0.00

0.00 Day's Range 0.00

0.222 52 Week Range 0.222

Market Cap

Previous Close

0.222

Open

-

Last Trade

Last Trade Time

Financial Volume

-

VWAP

-

Average Volume (3m)

0.00

Shares Outstanding

8,636,000

Dividend Yield

-

PE Ratio

1.66

Earnings Per Share (EPS)

0.13

Revenue

4.11M

Net Profit

1.15M

Sector

Prepackaged Software

Industry

Prepackaged Software

Website

www.ilyda.com

Headquarters

Athens, Attica, Grc

Founded

-

Ilyda Sa is listed in the Prepackaged Software sector of the London Stock Exchange with ticker 0P0V. The last closing price for Ilyda was 0.22 €. Over the last year, Ilyda shares have traded in a share price range of 0.222 € to 0.222 €.

Ilyda currently has 8,636,000 shares in issue. The market capitalisation of Ilyda is 1.92 € million. Ilyda has a price to earnings ratio (PE ratio) of 1.66.

No news to show yet.

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0.222	0.222	0.222	0	0	DE
4	0	0	0.222	0.222	0.222	0	0	DE
12	0	0	0.222	0.222	0.222	0	0	DE
26	0	0	0.222	0.222	0.222	0	0	DE
52	0	0	0.222	0.222	0.222	0	0	DE
156	0	0	0.222	0.222	0.222	0	0	DE
260	0	0	0.222	0.222	0.222	0	0	DE

0P0V - Frequently Asked Questions (FAQ)

What is the current Ilyda share price?

The current share price of Ilyda is 0.222 €

How many Ilyda shares are in issue?

Ilyda has 8,636,000 shares in issue

What is the market cap of Ilyda?

The market capitalisation of Ilyda is EUR 1.92M

What is the 1 year trading range for Ilyda share price?

Ilyda has traded in the range of 0.222 € to 0.222 € during the past year

What is the PE ratio of Ilyda?

The price to earnings ratio of Ilyda is 1.66

What is the cash to sales ratio of Ilyda?

The cash to sales ratio of Ilyda is 0.46

What is the reporting currency for Ilyda?

Ilyda reports financial results in EUR

What is the latest annual turnover for Ilyda?

The latest annual turnover of Ilyda is EUR 4.11M

What is the latest annual profit for Ilyda?

The latest annual profit of Ilyda is EUR 1.15M

What is the registered address of Ilyda?

The registered address for Ilyda is ADRIANEIOY 29, NEO PSYCHIKO, ATHENS, ATTICA, 11525

What is the Ilyda website address?

The website address for Ilyda is www.ilyda.com

Which industry sector does Ilyda operate in?

Ilyda operates in the PREPACKAGED SOFTWARE sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TCFTheracryf Plc	0.725p (38.10%)	7.56M
NMTNeometals Ltd	3.50p (27.27%)	346.81k
SCHOScholium Group Plc	44.00p (25.71%)	30.65k
FABFusion Antibodies Plc	10.15p (24.54%)	3.34M
PYXPyx Resources Limited	3.49p (22.24%)	8.43k
TM1Technology Minerals Plc	0.125p (-24.24%)	37.21M
QUIZQuiz Plc	0.70p (-18.60%)	3.67M
SYMESupply@me Capital Plc	0.003p (-17.81%)	168.35M
OBDOxford Biodynamics Plc	1.20p (-14.29%)	827.83k
ZENZenith Energy Ltd.	5.25p (-13.93%)	5.39M
TRPTower Resources Plc	0.0395p (5.33%)	539.51M
CPXCap-xx Limited	0.1825p (1.39%)	494M
NTVONativo Resources Plc	0.0019p (0.00%)	320.16M
DGIDg Innovate Plc	0.0225p (-13.46%)	208.21M
ENETEthernity Networks Ltd	0.1125p (2.27%)	207.56M

devil dog 96

devil dog 96 5 minutes ago

Tell everyone why you think they never took the 39 million shares off restriction if they need shares to dump? Why have they not taken 1 share off restriction since early 2021 if they need shares to dump?? Why would they issue new shares that will be unregistered and also have to wait a year before

CrossFireTrader

CrossFireTrader 5 minutes ago

Page 22 of 26, and If say I'm Bullish that'll set 280e off, and I'll be accused of pumping our little lottery ticket. I'm here for the long haul. I'm not here to sell at 0.016 or 0.02 or 0.03 or whatever his new price is. He actually likes GDVM a lot more than he lets on. Since you seem to be somew

Mr. Bill

Mr. Bill 9 minutes ago

https://measuringmyhealth.com/what-is-a-normal-pi-on-a-pulse-oximeter/

georgejjl

georgejjl 9 minutes ago

That is WRONG. The current standard of care is donepezil (Aricept) and memantine, etc.

MAB's still are an extremely small number of treatments for Alzheimer's in the USA and worldwide.

Good luck and GOD bless,

axelvento

axelvento 29 minutes ago

Q1 the first interim analysis of the vaccine’s efficacy is expected

Moderna’s mRNA-1647
Cytomegalovirus

MightyX

MightyX 32 minutes ago

Yet no one is innocent

BIG D 4

BIG D 4 33 minutes ago

WOW !! HAPPY NEW YEAR TO ALL THE LONGS HERE !! I HAVE 2 NAYSAYERS ON IGNORE SO I NEVER READ THEIR BS !! GO SAVING GRACE-- JJ AND ALL THE NEW POSTERS WHO ARE POSITIVE !! .02 CENTS TO START THE RUN TO ONE DOLLAR IS WHERE WE SHOULD BE !! THIS STOCK IS SUCH A GREAT BUY HERE !! I AM LOADED WITH 32 MILLI

MightyX

MightyX 33 minutes ago

The judicial system legitimizes prosecution

jondoeuk

jondoeuk 34 minutes ago

A new paper. From it: 'BNT221 was well tolerated across both DLs, with no dose-limiting toxicities of grade 3 or higher attributed to the T cell product observed. Specifically, no cytokine release, immune effector cell-associated neurotoxicity or macrophage activation syndromes were reported. A dose

benz280c

benz280c 35 minutes ago

Nice to see you are bullish. This quote may round out your knowledge.
"It is worthy to note that a new CUSIP has been approved by the CUSIP Global Services (CGS).
Subsequently, we have submitted a corporation action with FINRA for a Company name change, Ticker Symbol Change and Cusip

shajandr

shajandr 36 minutes ago

Sorry to read that you're still feeling sick. I posted a week or two ago about 41 bunnies and also some cats and dogs that were rescued from a home in Delaware county, Iowa and that were transferred to the DBQ county animal shelter. I just spoke with DaSqu_w and she went to the animal shelter to see

Lakota-45

Lakota-45 37 minutes ago

Will do, but I doubt they will listen !!!

~ Lol !!!

boi568

boi568 38 minutes ago

HokieHead

HokieHead 40 minutes ago

HokieHead

HokieHead 41 minutes ago

Get your facts straight, the halt was in the Canadian side as they are reviewing all the disclosures submitted, there’s ZERO issues in the US, it’s a fully reporting SEC company.

Lakota-45

Lakota-45 42 minutes ago

I agree with you 'farmI1234 !!!

I'm pretty sure most of the Savvy Investors, that have been paying attention,
have been loading the dips, and .0004's, for a while now.
I know I have, along with fishing down stream.

I doubt any Longs will get caught short,

CaptHowdy

CaptHowdy 44 minutes ago

RECOMMENDED.... nothing is offical yet, unnecessary twisting of facts to bolster your negative viewpoints. Thats news is two months old

axelvento

axelvento 44 minutes ago

Cancer vaccines: What’s ahead in 2025

The spotlight is on mRNA-4157 (V940)

https://gulfnews.com/special-reports/cancer-vaccines-whats-ahead-in-2025-1.500010233

facts_matter14

facts_matter14 45 minutes ago

Does this sound like a company with 16 products and a 17th on the way?

https://investorshub.advfn.com/uimage/uploads/2024/12/24/mwowsIMG_6034.png

.

HomerRomer

HomerRomer 45 minutes ago

More testimony videos from trial participants like the Australian news reel of Ern Heaven would be amazing. I would think that most of the people involved 9 years ago in the earlier phase studies have passed on since the average life expectancy is normally between 3-11 years after being diagnosed w

CaptHowdy

CaptHowdy 46 minutes ago

That's how to make money on the OTC. 🤦🏻‍♂️ Anyone could do it; only if the effort spent discounting the new leadership in place along with the turn around story underway was used to turn a profit vs. using 9yr old DD to bad mouth new CEO.

crescentmotor

crescentmotor 47 minutes ago

I think that is a bad precedent to start.

100% on parading a handful of Blarcamesine patients at the JPM conference. I highly doubt AVXL would involve itself with anecdotal gimmicks where there is no way possible to extrapolate isolated successes to meaningful conclusions about broad

Steady_T

Steady_T 49 minutes ago

MABS are the current standard of care, so Blarcamesine has to be better than the MABS, which is not saying much.

I suspect that if Blarcamesine was the equal of the MABS is would still be approved on safety and cost grounds.

As has been pointed out multiple times on the

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions